In another study released at ASCO, researchers treated 216 men with metastatic CRPC with PSMA-targeted radionuclide therapy, including 177Lu-J591 (n = 136), 177Lu-PSMA-617 (n = 38), Lu-J591 + Lu-PSMA-617 (n = 6), 225Ac-J591 (n = 7), and 90Y-J591 (n = 129).
Their goal was to analyze PSMA-targeted radionuclide therapy response by looking at imaging expression.
They found that 74.5% of the men had high PSMA expression (not all types of prostate cancer expresses the same level of PSMA), which was associated with significantly more frequent PSA decline. A total of 13 of the men who had no PSMA uptake still exhibited some level of PSA decline despite not having any PSMA uptake.
This study did demonstrate that the level of PSMA expression of a man’s prostate cancer, the stronger the association with the likelihood of their having a PSA response.
It would be interesting if the researchers would show us which of the PSMA treatments had a superior result, and if any of them was superior for those men who did not exhibit any PSMA expression.
Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT). PJ Vlachostergios, MJ Niaz, SA Mosallaie, et al
